ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2051

Characteristics and Comparison Of Patients With Cystic Fibrosis With and Without Arthritis

Heather O. Tory1, Karen Herlyn2, David Zurakowski3, Angela S. Pizzo4, Robert P. Sundel5 and Peter A. Merkel6, 1Rheumatology Program, Division of Immunology, Boston Children's Hospital, Boston, MA, 2Department of Rheumatology, University Hospital Schleswig-Holstein, Lübeck, Germany, 3Departments of Anesthesia and Surgery, Boston Children’s Hospital, Boston, MA, 4Mercy Hospital, Portland, ME, 5Division of Immunology, Boston Children's Hospital, Boston, MA, 6Division of Rheumatology, Vasculitis Center, University of Pennsylvania, Philadelphia, PA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: inflammatory arthritis, laboratory tests and musculoskeletal disorders

  • Tweet
  • Email
  • Print
Session Information

Title: Miscellaneous Rheumatic and Inflammatory Diseases II: Miscellaneous Rheumatic Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose: Cystic Fibrosis (CF) is a common genetic mutation in Caucasian populations. Many patients have musculoskeletal complaints and 12% develop arthritis, including CF arthropathy (CFA), a poorly understood entity of episodic mono or polyarthritis, and other inflammatory arthropathies. Prior studies have been limited to small patient cohorts showing no clear association with disease severity or complications, or specific laboratory results. Thus, diagnostic criteria are not well defined and the pathogenesis remains unclear. The goal of this study was to compare disease characteristics and laboratory findings between patients with CF with and without arthritis from a large cohort.

 

Methods: Patients with CF seen at 2 tertiary care hospitals over a 6 year period were screened for musculoskeletal symptoms via questionnaire or referral. Patients with symptoms underwent a comprehensive evaluation including chart review, medical history and physical examination by a rheumatologist, laboratory testing and pulmonary function testing. Patients were diagnosed with arthritis if they had physician documented evidence of joint effusion, warmth, or limited range of motion. Age- and gender-matched control patients with CF without arthritis were also evaluated.  Comparisons between cases and controls were made by univariate and multivariate logistic regression analyses to identify independent markers of arthritis.

Results: The study cohort consists of 25 patients with CF and arthritis and 72 without arthritis. Demographic features were similar with no differences in the presence of disease complications (Table 1). Univariate analysis did find a higher percentage of rheumatoid factor (RF) positivity in patients with arthritis compared to patients without arthritis (18% vs. 3%, p = 0.04), with no other between group differences (Table 2). Regression analysis suggested this association held (p=0.05) after controlling for other markers of disease severity (age, IgG level, and FEV1).

 

Conclusion: In this largest cohort to date, patients with CF and arthritis were more likely to have a positive RF compared to patients without arthritis, suggesting that the pathophysiology may be related to accumulation of antigenic immune markers. There were no other differences, indicating that the etiology and spectrum of disease may vary and requires additional exploration, including genotype evaluation and longitudinal follow-up.

Table 1. Comparison of demographic features and disease complications between groups

Patient Characteristics

Cystic Fibrosis Patients with Arthritis

(n=25)

Cystic Fibrosis Patients

without Arthritis

(n=72)

p value

Demographic features

 

 

 

Female, no. (%)

14 (56)

38 (53)

0.82

Age at visit, median (range) in years

25.1 (4.6-55.9)

26.6 (5-43.8)

0. 93

Body mass index, mean (SD) kg/m2

19.6 (3.9)

20.6 (3.6)

0.33

Family history of autoimmunity, no. (%)

0 (0)

4 (6)

0.57

 

 

 

 

Complications of cystic fibrosis, no. (%)

 

 

 

Allergic bronchopulmonary aspergilosis

2 (10)

8 (12)

1

Bowel obstruction

8 (35)

14 (20)

0.17

Diabetes mellitus/pancreatic

8 (35)

20 (29)

0.61

Hepatitis/cirrhosis

6 (26)

7 (10)

0.08

Hepatobiliary/gallbladder

4 (17)

9 (13)

0.73

Malabsorption/intestinal

19 (83)

57 (83)

1

Nasal polyps

16 (70)

34 (49)

0.15

Pulmonary

23 (100)

62 (90)

0.19

 

Table 2. Comparison of laboratory features among groups

 

Laboratory Features

Cystic Fibrosis Patients with Arthritis

(n=25)

Cystic Fibrosis Patients

without Arthritis

(n=72)

p value

Albumin, g/dL

3.9 (0.5)

3.9 (0.53)

0.83

ALT, units/L

28.8 (18.8)

37.3 (31.4)

0.21

Amylase, units/L

39.8 (23.6)

51.1 (32.9)

0.13

ANA present, no. (%)

3 (14)

13 (22)

0.54

AST, units/L

27.2 (17.5)

32.5 (24.3)

0.33

CH50, units/mL

232 (63)

206 (58)

0.15

Cholesterol, mg/dL

151 (50)

141.2 (43)

0.40

Immune complexes, median (IQR)

11.5 (5.8, 15)

9 (3, 12)

0.21

Creatinine, mg/dL

0.82 (0.38)

0.83 (0.26)

0.93

CRP, median (IQR) mg/dL

5.7 (3, 14.4)

3.1 (3, 18)

0.71

Cryoglobulin present, no. (%)

1 (5)

3 (5)

1

ESR, mm/hr

26.9 (21.6)

24 (23.1)

0.60

FEV1, % predicted

62.5 (26.2)

63.5 (29.8)

0.89

FVC, % predicted

75.5 (22.6)

78.8 (25.6)

0.61

Glucose, mg/dL

114 (59)

120 (81)

0.76

Hematocrit, %

38 (4)

39 (4)

0.23

IgG, mg/dL

1258 (441)

1383 (554)

0.33

Platelet, cells/uL

284 (110)

304 (92)

0.37

Rheumatoid factor present, no. (%)

4 (18)

2 (3)

0.04

Total bilirubin, mg/dL

0.45 (0.21)

0.47 (0.58)

0.84

Triglyceride, mg/dL

131 (94)

110 (63)

0.27

White blood cell, 103-cells/uL

9.4 (2.3)

9.7 (3.3)

0.75

Data are mean (SD) unless otherwise indicated. IQR = interquartile range.

 


Disclosure:

H. O. Tory,
None;

K. Herlyn,
None;

D. Zurakowski,
None;

A. S. Pizzo,
None;

R. P. Sundel,
None;

P. A. Merkel,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characteristics-and-comparison-of-patients-with-cystic-fibrosis-with-and-without-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology